术后放疗与N1期口腔及口咽鳞状细胞癌患者生存的关联
这项回顾性队列研究纳入美国国家癌症数据库2004年1月1日至2013年12月31日期间1467例口腔鳞状细胞癌和790例口咽鳞状细胞癌成人患者,均为pT1N1或pT2N1且无其他不良特征。控制人口学、病理及医院层面变量后,术后放疗与口腔鳞状细胞癌(HR 0.76;95%CI 0.63-0.92)和口咽鳞状细胞癌(HR 0.62;95%CI 0.41-0.92)总生存改善相关。分层分析中该关联在70岁以下及pT2患者中持续存在,但在70岁及以上及pT1患者中无统计学关联。
要点
- 术后放疗与pN1口腔鳞状细胞癌总生存改善相关(HR 0.76;95%CI 0.63-0.92)
- 术后放疗与pN1口咽鳞状细胞癌总生存改善相关(HR 0.62;95%CI 0.41-0.92)
- 70岁以下及pT2患者中该关联持续存在,70岁及以上及pT1患者中无统计学关联
核心结论
- 术后放疗可能与pN1口腔及口咽鳞状细胞癌患者生存改善相关,尤其是70岁以下或pT2患者。
研究设计与样本
- 回顾性队列研究,从美国国家癌症数据库2004年1月1日至2013年12月31日期间识别1467例口腔鳞状细胞癌和790例口咽鳞状细胞癌成人患者,均为pT1N1或pT2N1且无其他不良特征。
- 排除接受辅助化疗或姑息性放疗或具有不良病理特征的患者。
- 统计分析包括χ2检验和Cox比例风险回归分析,数据分析时间为2015年11月10日至2016年6月30日。
主要发现
- 口腔鳞状细胞癌患者1467例(男性842例[57.4%];女性625例[42.6%];平均[SD]年龄61.3[13.8]岁),其中740例(50.4%)接受术后放疗。
- 口咽鳞状细胞癌患者790例(男性584例[73.9%];女性206例[26.1%];平均[SD]年龄58.2[10.3]岁),其中449例(56.8%)接受术后放疗。
- 控制患者人口学、病理特征及医院层面变量后,术后放疗与口腔鳞状细胞癌总生存改善相关(HR 0.76;95%CI 0.63-0.92),与口咽鳞状细胞癌总生存改善相关(HR 0.62;95%CI 0.41-0.92)。
- 分层分析中,70岁以下患者口腔鳞状细胞癌HR 0.77(95%CI 0.61-0.97)、口咽鳞状细胞癌HR 0.48(95%CI 0.31-0.75);pT2患者口腔鳞状细胞癌HR 0.64(95%CI 0.43-0.96)、口咽鳞状细胞癌HR 0.56(95%CI 0.32-0.95)。
- 70岁及以上患者口腔鳞状细胞癌HR 0.78(95%CI 0.58-1.06)、口咽鳞状细胞癌HR 1.55(95%CI 0.63-3.82);pT1患者口腔鳞状细胞癌HR 0.80(95%CI 0.60-1.07)、口咽鳞状细胞癌HR 0.66(95%CI 0.35-1.24),均无统计学关联。
关键数值与推荐
- 头颈癌指南推荐:对于pT1N1或pT2N1且无其他不良特征的患者,考虑辅助术后放疗;该推荐最近针对口咽鳞状细胞癌进行了修改。
临床怎么用
- 作者认为,术后放疗可能与pN1口腔及口咽鳞状细胞癌患者生存改善相关,尤其是70岁以下或pT2患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The guidelines for head and neck cancer recommend consideration of adjuvant postoperative radiotherapy (PORT) for patients with pT1N1 or pT2N1 disease in the absence of other adverse features. This recommendation was recently changed for oropharyngeal (OP) squamous cell carcinoma (SCC). OBJECTIVE: To examine the use and outcomes of PORT for N1 OP SCC and oral cavity (OC) SCC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study identified 1467 adult patients with OC SCC and 790 patients with OP SCC with pT1N1 or pT2N1 disease in the absence of other adverse features from the National Cancer Database from January 1, 2004, to December 31, 2013. Patients who received adjuvant chemotherapy or palliative radiotherapy or who had adverse pathologic features were excluded. Statistical analysis included χ2 tests and Cox proportional hazards regression analysis. Data were analyzed from November 10, 2015, to June 30, 2016. MAIN OUTCOMES AND MEASURES: Overall survival. RESULTS: Of the 1467 patients with OC SCC (842 men [57.4%]; 625 women [42.6%]; mean [SD] age, 61.3 [13.8] years), 740 (50.4%) received PORT. Of the 790 patients with OP SCC (584 men [73.9%]; 206 women [26.1%]; mean [SD] age, 58.2 [10.3] years), 449 (56.8%) received PORT. After controlling for patient demographics, pathologic characteristics, and hospital-level variables, PORT was associated with improved overall survival for patients with OC SCC (hazard ratio [HR], 0.76; 95% CI, 0.63-0.92) and OP SCC (HR, 0.62; 95% CI, 0.41-0.92) with pN1 disease without adverse features. On stratified analysis, this association persisted for patients younger than 70 years (OC SCC HR, 0.77; 95% CI, 0.61-0.97; OP SCC HR, 0.48; 95% CI, 0.31-0.75) and those with pT2 disease (OC SCC HR, 0.64; 95% CI, 0.43-0.96; OP SCC HR, 0.56; 95% CI, 0.32-0.95), but there was no association with overall survival among patients 70 years or older (OC SCC HR, 0.78; 95% CI, 0.58-1.06; OP SCC HR, 1.55; 95% CI, 0.63-3.82) and those with pT1 disease (OC SCC HR, 0.80; 95% CI, 0.60-1.07; OP SCC HR, 0.66; 95% CI, 0.35-1.24). CONCLUSIONS AND RELEVANCE: PORT may be associated with improved survival in patients with pN1 OC and OP SCC, especially in those younger than 70 years or those with pT2 disease.
引用
- Chen MM, Harris JP, Hara W, et al. Association of Postoperative Radiotherapy With Survival in Patients With N1 Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2016. PMID: 27832255. doi:10.1001/jamaoto.2016.3519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。